Observational study of patients treated with lercanidipine in conditions of clinical practice in the Czech republic

Czech version

Authors: M. Souček ¹; Jiří Slíva ^2,3 ; J. Suchopár ⁴
Authors‘ workplace: II. interní klinika LF MU a FN U sv. Anny v Brně ¹; Farmakologický ústav 2. LF UK, Praha ²; Ústav farmakologie 3. LF UK, Praha ³; Infopharm, a. s., Praha ⁴
Published in: Kardiol Rev Int Med 2014, 16(2): 123-126
Category: Cardiology Review

Overview

Lercanidipine is a calcium ion channel inhibitor that is used in the treatment of mild to moderate hypertension at dosages from 10 to 20 mg. The authors of this article summarize its use in an observational trial performed in the Czech republic in 375 patients with essential arterial hypertension. It was demonstrated the achievement of primary endpoint, i.e. significantly decreased of blood pressure. This was accompanied by a relatively small change of heart rate and positive safety profile.

Keywords:
lercanidipine –⁠ hypertension –⁠ oedemas –⁠ calcium ion channel inhibitors

Sources

1. Barrios V, Escobar C, Navarro A et al [online]. Available from: http:/ / www.ncbi.nlm.nih.gov/ pubmed?term=LAURA%20Investigators%5BCorporate%20Author%5DLercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract 2006; 60 : 1364 –⁠ 1370.

2. Burnier M, Gasser UE. Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opin Pharmacother 2007; 8 : 2215 –⁠ 2223.

3. Pruijm MT, Maillard MP, Burnier M. Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine. Vasc Health Risk Manag 2008; 4 : 1159 –⁠ 1166.

4. Makarounas ‑⁠ Kirchmann K, Glover ‑⁠ Koudounas S, Ferrari P. Results of a meta‑analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther 2009; 31 : 1652 –⁠ 1663. doi: 10.1016/ j.clinthera.2009.08.010.